Dr. Chiara Cremolini on the Updated Results of the TRIBE2 Study for Unresectable Colorectal Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Chiara Cremolini, MD, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer.

Cancer Network spoke with Chiara Cremolini, MD, of Azienda Ospedaliero-Universitaria Pisana, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer.

Related Videos
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Stacey Cohen, MD, an expert on colorectal cancer
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
A panel of 5 experts on colorectal cancer
Aparna Parikh, MD, an expert on colorectal cancer
Related Content
COVID-19 Pandemic Has Exacerbated CRC Surgery Disparities

COVID-19 Pandemic Has Exacerbated CRC Surgery Disparities

April 17th 2024
Article

Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.

New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.

Joleen Hubbard, MD, Highlights The “Exciting Space” Of Metastatic CRC

December 11th 2023
Podcast

New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.

Blood-Based Test May Help Detect CRC in Average-Risk Population | Image Credit: © Dr_Microbe - stock.adobe.com.

Blood-Based Test May Help Detect CRC in Average-Risk Population

April 7th 2024
Article

The PREEMPT trial analyzed samples from 27,010 average-risk adults to determine the specificity of detecting colorectal cancer.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.

Personalized Vaccine Yields Early PFS Benefit in Metastatic MSS-CRC

April 2nd 2024
Article

Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.

Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.

Microbiome Signature Differences May Impact Rectal Cancer Treatment Effect

March 30th 2024
Article

Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.